Document is current

Any future updates will be listed below

Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?

Crossref DOI link: https://doi.org/10.1016/j.nrleng.2020.10.009

Published Print: 2021-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

About CrossMark